With PARP inhibitors and anti-PD1/PDL1 inhibitors included as treatment options based on genetic mutations, as well as the continuation of clinical trials and research finding new targets and patient-specific mutations, we see a paradigm shift in the drug management of PCa. Here, CD274 is linked to posterior cortical atrophy.